Important Notice:
Discontinuation of the Alexion Assure Risk Management Portal
The ULTOMIRIS® (ravulizumab rch) and SOLIRIS® (eculizumab rmc) Risk Management Portal is permanently closed.
What does this mean?
Prescribers are no longer required to:
- register a patient for ULTOMIRIS or SOLIRIS therapy
- submit a Certificate of Vaccination for patients that will receive ULTOMIRIS or SOLIRIS
- include a Unique Patient Identifier in orders for ULTOMIRIS or SOLIRIS
It remains critically important for patients receiving ULTOMIRIS or SOLIRIS, to complete meningococcal vaccination prior to beginning and during treatment. Alexion will continue to provide annual vaccination reminders and educational materials for healthcare professionals and patients to highlight the risks of meningococcal infection.
Materials available for download:
Educational materials will continue as part of Alexion’s risk minimisation activities and are available to download at any time via clicking the button below and logging into the Healthcare Professionals portal.
Do you have questions or need further assistance?
Get in touch with Alexion for support.